指南与共识消化内镜消化道肿瘤与早癌胰腺与胆道疾病

AGA临床实践更新:壶腹部肿瘤管理专家综述

AGA Clinical Practice Update on Management of Ampullary Neoplasms: Expert Review.
指南 / 共识 · Clin Gastroenterol Hepatol · 2026-09-10

美国胃肠病协会(AGA)发布的专家综述,针对壶腹部肿瘤(占胃肠癌0.6%-0.8%)的管理提出15条最佳实践建议。内容涵盖内镜评估、活检数量、超声内镜分期、内镜下乳头切除术的适应证与禁忌证、术后并发症预防及 surveillance 策略,强调多学科协作。

要点

  • 壶腹部腺瘤评估应使用侧视十二指肠镜,活检至少6块。
  • 内镜下乳头切除术适用于无恶变征象、尺寸<4-5cm、导管内延伸≤1cm的病变。
  • 术后3个月开始监测,无残留者6、12个月复查,之后每年至少5年。

核心结论

  • 壶腹部肿瘤管理需高质量内镜评估、完整切除及个体化监测以降低复发和早期诊断癌症。

研究设计与样本

  • 由AGA临床实践更新委员会委托并批准的专家综述,基于文献回顾和专家意见,未进行系统评价,建议无正式证据等级。

主要发现

  • 壶腹部腺癌5年生存率20%-75%,取决于诊断分期。
  • 20%-40%的壶腹部腺瘤含有恶性成分。
  • 内镜下乳头切除术后监测从3个月开始,无残留者6、12个月复查,之后每年至少5年。

关键数值与推荐

  • 建议1:使用侧视十二指肠镜评估壶腹部腺瘤。
  • 建议2:至少取6块活检,尤其溃疡或硬结区域。
  • 建议3:超声内镜用于分期和评估导管内延伸,但小于1cm且无担忧特征者可不做。
  • 建议4:内镜下乳头切除术适合边界清晰、大小<4-5cm、非脆性、质软、导管内延伸≤1cm的病变。
  • 建议5:导管内延伸>1cm建议外科会诊;<1cm可内镜治疗并密切监测。

临床怎么用

  • 临床中应使用侧视十二指肠镜评估壶腹部腺瘤,确保至少6块活检。
  • 根据病变特征选择内镜下乳头切除术,严格掌握禁忌证。
  • 术后采用预防性胰管支架、NSAIDs和水化减少胰腺炎,并按建议监测。

局限性

  • 未进行系统评价,建议基于文献回顾和专家意见,无正式证据质量评级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: Although ampullary neoplasia is a rare entity and represents 0.6%-0.8% of gastrointestinal cancers, the incidence among young adults has risen over the past 20 years. Most ampullary tumors are sporadic, but a few genetic syndromes substantially increase the risk of ampullary neoplasia. Compared with other neoplastic pancreaticobiliary entities, there is a relative lack of guidance on best practices for management of ampullary lesions. Ampullary cancer is associated with a 5-year survival rate ranging from 20% to 75%, depending on the stage of diagnosis. Ensuring high-quality endoscopic assessment and treatment with complete resection will decrease recurrence risk and identify patients at an earlier stage. METHODS: This expert review was commissioned and approved by the American Gastroenterological Association Institute Clinical Practice Updates Committee and the American Gastroenterological Association Governing Board to provide timely guidance on a topic of high clinical importance to the American Gastroenterological Association membership and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. These Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these Best Practice Advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. BEST PRACTICE ADVICE STATEMENTS BEST PRACTICE ADVICE 1: Assessment for ampullary adenomas is best conducted using a side-viewing duodenoscope, because ampulla visualization and access for biopsies with a standard forward-viewing gastroscope is limited. Furthermore, use of a duodenoscope allows for a more careful biopsy, avoiding the pancreatic orifice to minimize postprocedure pancreatitis risk. BEST PRACTICE ADVICE 2: A significant proportion (20%-40%) of ampullary adenomas harbor malignancy; therefore, at least 6 biopsies should be obtained to assess histopathology, especially from ulcerated or indurated areas. BEST PRACTICE ADVICE 3: Endoscopic ultrasound assessment is valuable for staging and determination of the extent (if any) of intraductal extension and should be considered for each patient with an ampullary adenoma that is potentially amenable to endoscopic resection, barring lesions smaller than 1 cm with no worrisome clinical or endoscopic features. BEST PRACTICE ADVICE 4: Endoscopic characteristics of an ampullary adenoma that suggest it is benign and render it most amenable to endoscopic papillectomy include: well-defined margins, size less than 4-5 cm, a nonfriable lesion, and a lesion that is soft to endoscopic probing and with intraductal extension limited to 1 cm or less. BEST PRACTICE ADVICE 5: For ampullary adenomas with significant (>1 cm) intraductal extension, consultation for consideration of surgical resection is suggested. Lesions with minimal (<1 cm) intraductal involvement may be amenable to endoscopic treatment with close surveillance. BEST PRACTICE ADVICE 6: Three definitive contraindications to endoscopic papillectomy are: metastatic spread, invasive cancer that extends beyond the mucosal layer, and with >1cm intraductal extension in a surgically fit patient. Relative contraindications or factors that warrant further consideration include lesions over 5 cm in size, early-stage/T1 cancers and concerns surrounding patients with limited follow-up adherence. BEST PRACTICE ADVICE 7: In cases where endoscopic resection is not feasible, and biliary obstruction resulting in significant jaundice or when cholangitis is present, biliary drainage with or without sphincterotomy and self-expandable metal stent placement may be considered at the discretion of the surgeon. BEST PRACTICE ADVICE 8: Avoid prepapillectomy biliary and pancreatic sphincterotomies to minimize the risk of incomplete histopathologic assessment due to electrocautery artifact and bleeding prior to resection. BEST PRACTICE ADVICE 9: En bloc snare resection should be performed when feasible. Submucosal injection is generally not required but may be beneficial for laterally spreading components of the lesion along the duodenal wall. BEST PRACTICE ADVICE 10: Prophylactic pancreatic duct stenting, rectal nonsteroidal anti-inflammatory drugs, and high-volume hydration with lactated Ringer's solution should be used to minimize postpapillectomy pancreatitis. BEST PRACTICE ADVICE 11: Standard hemostasis techniques, such as epinephrine injection, electrocoagulation, use of hemoclips, argon plasma coagulation, and hemostatic sprays, may all be carefully employed for treating bleeding from endoscopic papillectomy. BEST PRACTICE ADVICE 12: Following endoscopic papillectomy, surveillance should begin at 3 months, with side-viewing duodenoscopy and biopsy of the resection scar and any abnormal area. If there is no residual adenoma, surveillance should be repeated at 6 months and 12 months, and then annually for at least 5 years. Surveillance beyond 5 years should be individualized based on recurrence risk, comorbidity, and life expectancy. In familial adenomatous polyposis, surveillance intervals should be individualized according to ampullary, gastric, and duodenal disease burden. BEST PRACTICE ADVICE 13: For adenomas >3 cm resected piecemeal or those with positive margins, consider adjunct thermal ablation and ductography. Perform this follow-up every 2-3 months until eradication is confirmed via biopsy. BEST PRACTICE ADVICE 14: There are some reports of recurrence or cancer developing more than 5 years after resection; however, these cases are rare. Due to the limited number of such reports, the decision to continue endoscopic surveillance beyond 5 years should be individualized based on the overall health and life expectancy of the patient. If high-risk features are present, long-term endoscopic monitoring is required. BEST PRACTICE ADVICE 15: Patients with high-grade dysplasia, incomplete resection, or suspected malignancy should be discussed by a multidisciplinary team that includes gastroenterologists, surgeons, and oncologists.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Barakat M, Maranki J, Irani S, et al. AGA Clinical Practice Update on Management of Ampullary Neoplasms: Expert Review. Clin Gastroenterol Hepatol. 2026. PMID: 42720640. doi:10.1016/j.cgh.2026.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。